Submission is based on Phase 3 REZILIENT3 data in first-line EGFR ex20ins NSCLC Nov. 12, 2026 -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced their partner Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-base

Human Neural Stem Cell Transplants Offer a Novel Approach to Treating Huntington’s Disease Acquisition Includes Rights Relating to a Stem Cell-Derived Clinical Trial for Huntington’s Disease (REGEN4HD), a Phase 1b/2a Clinical Trial Currently Enrolling Patients NeuroAirmid Shareholders Received $4.7 Million in Cash and Equity at Closing and are Eligible to Receive up to $5 Million on the First Anniversary of Closing and up to $48 Million in Success-based Milestones UCI Received a $12 Million Clin

Anzupgo® (delgocitinib) cream has been approved by China’s National Medical Products Administration (NMPA) for adult patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate. The approval is supported by positive results from the DELTA China phase 3 trial, together with the broader delgocitinib clinical program, including DELTA 1, DELTA 2, DELTA 3 and DELTA Force.1-7 The approval reflects LEO Pharma’s commitment to improving care

Regeneron Pharmaceuticals on Thursday reported upbeat results from a Phase II study of the natriuretic peptide receptor 1 (NPR1)-blocking antibody baloncibart (REGN7544) in adults with postural orthostatic tachycardia syndrome (POTS), showing a notable reduction in the exaggerated heart rate response to standing with a single dose. The company plans to advance the therapy into late-stage testing next year. The PINNACLE trial randomly assigned 82 patients to a single subcutaneous dose of baloncib

Nine-month NHP durability and favorable GLP toxicology pro first-in-human phase 1/2 trial in 2027 Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation in vivo CRISPR gene editing platform to create potential one-time curative therapies, recently presented new preclinical data on its lead developmental candidate, MB-111, at the American Heart Association Scientific Sessions, held November 6–9 in Chicago. MB-111 is a potential first-in-class, single-dose

Addex Therapeutics’ neuropsychiatric-focused spinout has raised $105 million in series B funds to bankroll a planned phase 2 study of its schizophrenia treatment. Switzerland-based Addex originally launched Neurosterix in April 2024, armed with a $65 million series A led by funds affiliated with life sciences investment firm Perceptive Advisors. Neurosterix is helmed by CEO Fred Callori, who is also a managing director at Perceptive. In a Wednesday release, Addex didn’t identify the investors in

Following an earlier bacterial vaccine development collaboration, AstraZeneca has acquired partner Omniose for an undisclosed amount, with the biotech becoming a wholly-owned subsidiary of the UK drugmaker's infectious disease unit. "Omniose's bioconjugation platform represents a differentiated approach to engineering conjugate vaccines and strengthens our ability to develop novel vaccines against serious bacterial infections," said Benjamin Moutier, AstraZeneca's SVP of infectious disease. The

Hangzhou Eli Radiopharma concluded a series A round, raising nearly RMB 400 million ($60 million), to propel its oncology- and neurology-directed radiopharmaceutical assets into clinical development. "Moving our pipeline toward the clinic is a critical next step in translating our research into meaningful advances for patients," said Eli Radiopharma CEO and founder Feng Yu. "We remain focused on addressing unmet clinical needs and strengthening our R&D and clinical development capabilities." The

The proceeds will also fund the expansion of the company’s neurodegeneration programmes. Credit: H_Ko/Shutterstock.com. Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of zalsupindole (DLX001), an orally bioavailable neuroplastogen. The company will advance zalsupindole into Phase II development and finance a broader pipeline expansion. The drug is being designed to treat psychiatric and psychological disorders. In animal models, single

RMAT designation provides early and frequent FDA engagement to support planned pivotal development of Senza5 CART5 Therapy may be eligible for priority review and accelerated approval if applicable criteria are met Orphan Drug Designation, granted in July 2026, provides development incentives to support Senza5 CART5 in T-cell lymphoma Nov. 10, 2026 -- Vittoria Biotherapeutics, Inc. (“Vittoria” or the “Company”), a clinical-stage immunotherapy company developing engineered T-cell therapies, tod